DaeWoong Pharmaceutical Announces Positive Safety Review for Bersiporocin
DaeWoong Pharmaceutical Co., Ltd. announced that its idiopathic pulmonary fibrosis (IPF) drug candidate, Bersiporocin (DWN12088), received a recommendation to continue its global Phase 2 clinical trial following a positive safety review.
- 94 patients enrolled out of 102 planned across Korea and the U.S.
- Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study.
The IDMC conducted an in-depth evaluation of interim safety data from 89 enrolled patients and found no significant safety concerns that would impact the trial's continuation.
The study is progressing as planned, with approximately 92% of the target population enrolled to date.
Author's summary: DaeWoong Pharmaceutical's Bersiporocin receives positive safety review.
More News
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- West Indies ease past Bangladesh in first T20I
- Three resilient UK multinationals global managers are excited about | Trustnet
- Jensen Ackles back on 'Tracker' 3.2 to amp up the suspense
- Battlefield 6 REDSEC battle royale to officially launch soon
- Comment | A spate of dealer anniversaries offers hope amid art market doomerism
- Photos: Friends of Maple Grove Cemetery hosts Trunk or Treat event – QNS
- Battlefield 6's Battle Royale Mode Is Called REDSEC, Is Free-To-Play, And Launches Tomorrow
- Winners and losers from Argentina’s pivotal midterm election
- Acres.com to collaborate with UA System’s Fryar Center - Talk Business & Politics